Merck’s Life Science business has entered into a non-binding memorandum of understanding (MOU) with the South Korean Ministry of Trade, Industry and Energy (MOTIE), and Daejeon City to establish a new bioprocessing production facility, to be known as the Asia Pacific BioProcessing Production Centre.
It will be situated in South Korea’s Daejeon City and will help biotech and pharmaceutical clients in the region with commercial production.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Merck also plans to collaborate with the Daejeon government to offer help to biotech firms in the Daedeok research complex in Daejeon, and to forge partnerships in bio-research with major Korean universities.
Merck executive board member and life science CEO Matthias Heinzel stated: “South Korea is an emerging global leader in the biotech industry, and this MoU demonstrates Merck’s commitment to the region by working closely with the government to better support our customers.
“The proposed facility would play a vital role in fulfilling demand in the Asia Pacific region while representing an important hub for further biopharma industry development in South Korea.”
Merck is a science and technology firm with operations across life science, healthcare and the electronics industries.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDaejeon mayor Jang Woo Lee stated: “Daejeon is the birthplace of the Korean biotech industry. Today it’s where companies, big and small, are intensely focused on technological innovation and talent development to bring new and novel therapies to market.
“Together with Merck, this planned investment cooperation will help support Daejeon’s growth to become a world-class biotech hub.”
